Related Experiment Video

Updated: Sep 28, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K

The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients

Dina Abushanab1, Mohammed Eldebs2, Ahmed Basha1

  • 1Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.

Current Problems in Cardiology
|March 28, 2022
PubMed

Insights

Optimizing COVID-19 management for cardiovascular disease (CVD) patients did not reduce overall health care costs. While non-critically ill patients saw cost reductions, critically ill patients experienced significant cost increases, raising overall expenses.

Area of Science:

  • Health Economics
  • Cardiology
  • Infectious Diseases

Background:

  • Cardiovascular diseases (CVD) are a significant comorbidity in COVID-19 patients.
  • Optimizing COVID-19 management protocols is crucial for improving patient outcomes and managing healthcare resources.
  • Understanding the economic impact of protocol revisions in this vulnerable population is essential.

Purpose of the Study:

  • To evaluate the impact of an optimized COVID-19 management protocol on healthcare costs in patients with pre-existing cardiovascular diseases (CVD).
  • To determine whether evidence-based protocol optimization led to cost savings or increases from a healthcare perspective.

Main Methods:

  • Retrospective cohort study conducted at Hamad Medical Corporation, Qatar.
  • Analysis of direct medical costs for COVID-19 patients with pre-existing CVD, adjusted to 2021 values.
  • Comparison of costs before and after the revision of the initial COVID-19 management protocol.

Main Results:

  • For non-critically ill patients, costs decreased from QAR 15,447 (USD 4243) to QAR 4337 (USD 1191) per patient, a reduction of QAR 11,110 (USD 3051).
  • For critically ill patients, costs increased from QAR 202,094 (USD 55,505) to QAR 292,856 (USD 80,433) per patient, an added cost of QAR 90,762 (USD 24,928).
  • Overall, protocol optimization increased healthcare costs by QAR 80,529 (USD 22,117) per patient, irrespective of critical care status.

Conclusions:

  • The optimization of initial COVID-19 management protocols in patients with pre-existing CVD did not result in overall healthcare cost reduction.
  • Critically ill patients with CVD experienced a substantial increase in healthcare costs post-protocol optimization.
  • Further research is needed to explore cost-effective strategies for managing COVID-19 in high-risk cardiovascular populations.

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.5K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
52
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
46
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
60
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
42
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
76